Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | HTR3A | P46098 | 2/20 | 0.36 |
| ▸ | LCK | P06239 | 5/20 | 0.36 |
| ▸ | ITK | Q08881 | 5/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144332 | 0.84 | CLK1 (0.33) | LCKITKAURKB | |
| SCHEMBL139347 | 0.67 | AURKB (0.50) | CHRNA7HTR3ALCKITKAURKB | |
| SCHEMBL4115070 | 0.63 | MPO (0.51) | — | |
| SCHEMBL140611 | 0.62 | ITK (0.81) | LCKITKAURKBIRAK4 | |
| SCHEMBL178954 | 0.62 | LCK (0.69) | LCKITKAURKBIRAK4 | |
| SCHEMBL23095399 | 0.59 | IRAK4 (0.44) | CHRNA7HTR3AIRAK4 | |
| SCHEMBL10516437 | 0.59 | LTB4R (0.47) | — | |
| SCHEMBL14693733 | 0.58 | MAOB (0.59) | — | |
| SCHEMBL30521645 | 0.58 | HRH3 (0.46) | CHRNA7HTR3A | |
| SCHEMBL2453113 | 0.56 | CASP3 (0.61) | LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2408769-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | Glaxo Group Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106016-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | CHRNA7 4722/4885HTR3A 4588/4885LCK 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.